Hikma Pharmaceuticals PLC Annual Report 2014 DIRECTORS REPORT Directors Report The Directors submit their report together with the audited financial statements for the year ended 31 December 2014.
This report forms the management report for the purposes of the Disclosure and Transparency Rules.
Readers are asked to cross refer to the other sections of the Annual Report to the extent necessary to meet Hikmas reporting obligations as follows statements that are not applicable have been excluded : Details of long term incentive schemes: Directors remuneration report, page 105 Creditor payment policy Financial Hikmas policy, which is also applied by the Group and will continue Principal activity in respect of the 2015 financial year, is to settle terms of payment The principal activities of the Group are the development, with all suppliers when agreeing the terms of each transaction and manufacture and marketing of a broad range of generic and to ensure that suppliers are made aware of and abide by the terms in-licensed pharmaceutical products in solid, semi-solid, liquid and of payment.
Trade creditors of Hikma at 31 December 2014 were injectable final dosage forms.
The Groups pharmaceutical operations equivalent to 74days purchases 2013: 73 days, based on the are conducted through three business segments: Branded, Injectables average daily amount invoiced by suppliers during the year.
The majority of the Groups operations are in the Donations MENA region, the USand Europe.
The Group does not have overseas During the year the Group made charitable donations of branches within themeaning of the Companies Act 2006. approximately $2.0 million 2013: $6.2 million : The Groups net sales, gross profit and operating profit are shown by business segment in Note 4 to the consolidated financial Amount donated Amount donated Type of donation in2013 $ in 2014 $ statements.
Hikma has not capitalised any interest payments.
Local charities serving communities 5,098,321 1,489,484 Results inwhich the Group operates The Groups profit for the year in 2014 was $282 million Medical donations in kind 1,105,773 518,189 2013:$216 million.
Political Nil Nil Total 6,204,094 2,007,673 Dividend The Board is recommending a final dividend of 15 cents per share Group policy prohibits the payment of political donations.
approximately 9.94 pence 2013: 13 cents and a special dividend Research and development of 6cents per share approximately 4.0 pence.
The special dividend The Groups investment in research and development R&D during reflects the exceptional performance of the Generics and Injectables 2014 represented 3.7% of Group revenue 2013: 2.9%.
Additionally, segments over the period.
The proposed dividends will be paid the Group invested extensively in the purchase of certain products.
on 21 May 2015 to shareholders on the register on 17 April 2015, Further details on the Groups R&D activities can be found on subject to approval at the Annual General Meeting on 14 May 2015. page39.
An interim dividend of 7.0 cents per share plus a special dividend of 3.0 cents was paid on 26 September 2014 together approximately Related party transactions 6.75pence per ordinary share 2013: 10 cents.
The total dividend Details of related party transactions are included in Note 38 of the for the year 2014 is 31 cents per share 2013: 27.0cents, of which financial statements on page 162.
110 Corporate governance Going concern Significant contracts The Directors of Hikma Directors believe that the Group is well Due to the nature of the Groups business, members of the Group diversified due to its geographic spread, product diversity and large are party to agreements that could alter or be terminated upon customer and supplier base.
The Group operates in the relatively a change of control of the Group following a takeover.
However, defensive generic pharmaceuticals industry which the Directors none of these agreements is individually deemed to be significant expect to be less affected by economic downturns compared in terms of its potential impact on the business of the Group to other industries.
While a new bridge loan facility, which was taken as a whole.
The Directors are not aware of any agreements used to finance the cash consideration of $225 million for the between Hikma and its Directors or employees that provide for Bedford acquisition in July, increased the Groups total debt, the compensation for loss of office or employment that occurs because Groups overall net debt position of $274 million at 31 December of a takeover bid.
2014 was broadly in line with the position of $267 million at There are no persons, with whom Hikma has contractual or 31 December 2013, reflecting strong cash flow generation in other arrangements, who are deemed to be essential to the business 2014.
Operating cashflow in 2014 was $425 million 2013: of Hikma.
The Group has $839 million 2013: $234 million of Auditors undrawn short-term and long-term banking facilities, in addition Each person who was a Director of Hikma at the date when this to $180 million 2013: $142 million of unutilised import and report was approved confirms that: export financing limits.
These facilities are well diversified across the subsidiaries of the Group and are with a number of financial f So far as the Director is aware, there is no relevant audit information institutions.
The Groups forecasts, taking into account reasonable ofwhich Hikmas auditors are unaware possible changes in trading performance, facility renewal sensitivities f The Director has taken all the steps that he ought to have taken as and maturities of long-term debt, show that the Group should aDirector to make himself aware of any relevant audit information be able to operate well within the levels of its facilities and their andtoestablish that Hikmas auditors are aware of that information related covenants.
This confirmation is given and should be interpreted in accordance After making enquiries, the Directors believe that the Group with the provisions of section 418 of the Companies Act 2006. is adequately placed to manage its business and financing risks Deloitte LLP has expressed its willingness to continue in office successfully despite the current uncertain economic and political asauditors and a resolution to reappoint them will be proposed outlook.
The Directors have a reasonable expectation that the Group atthe forthcoming Annual General Meeting.
has adequate resources to continue in operational existence for the foreseeable future.
The Directors therefore continue to adopt the going concern basis inpreparing the financial statements.
111 Hikma Pharmaceuticals PLC Annual Report 2014 DIRECTORS REPORT continued As at 31 December 2014: Directors The names of the Directors as at the date of this report, together Issued during Type Nominal value In issue the year with details of their roles, backgrounds and abilities, are set out Ordinary 10 pence 198,632,039 587,711 in the Directors biographies on pages 56 to 59.
Details of the independence of Non-Executive Directors are set out in thereport During 2014, Hikma issued ordinary shares solely pursuant to the oncorporate governance on page 67.
Mr Pat Butler was appointed exercise of options under the Stock Option Plan, 2005 Long Term asa Directoreffective 1 April 2014, Sir David Rowe-Ham and Incentive Plan and 2009 Management Incentive Plan.
MrSamihDarwazah retired as Directors on 15 May 2014 and There are no specific restrictions on the size of a holding DrPamela Kirby was appointed as a Director effective from or on the transfer of shares, which are both governed by the 1 December 2014.
Otherwise, all the Executive and Non-Executive general provisions of Hikmas Articles of Association the Articles Directors served Hikma throughout the year.
The Directors are not aware of any It is the Boards policy that all Directors should retire and seek agreements between holders of Hikmas shares that may have re-election on an annual basis.
Accordingly, Mr SaidDarwazah, resulted in restrictions on the transfer of securities or on voting MrMazen Darwazah, Mr Robert Pickering, Mr Ali Al-Husry, rights.
No personhas any special rights with regard to the control MrBreffni Byrne, Mr Michael Ashton, Dr Ronald Goode, ofHikmas share capital and all issued shares are fully paid.
Hikma has MrPatButler and Dr Pamela Kirby will retire at the Annual General not placed anyshares into treasury during the period under review.
All Directors will seek election or re-election at the Annual General Meeting.
Shareholders are referred to the Effectiveness Share buy back report on pages 68 to 69, which provides further detail on the At the Annual General Meeting on 15 May 2014, shareholders balance of skills and experience onthe Board.
gave the Directors authority to purchase shares from the market up to an amount equal to 10% of Hikmas issued share capital at Indemnities that time.
This authority expires at the earlier of 30 June 2015 or The Directors benefit from qualifying third-party indemnities made the 2015 Annual General Meeting, which is scheduled for 14 May by Hikma which were in force during the year and as at the date of 2015.
The Directors have not used this authority during the year, this report.
These indemnities are uncapped in amount in relation to but are proposing to renew this authority at the 2015 Annual losses and liabilities which Directors may incur to third parties in the General Meeting.
course ofthe performance of their duties.
Share issuance At the Annual General Meeting on 15 May 2014, the Directors were Equity authorised to issue relevant securities up to an aggregate nominal Capital structure amount of 6,605,233, and to be empowered to allot equity Details of the issued share capital, together with movements in the securities for cash on a non pre-emptive basis up to an aggregate issued share capital during the year can be found in Note 31 to the nominal amount of 990,785, at any time up to the earlier of financial statements.
Hikma has one class of ordinary shares which the date of the 2015 Annual General Meeting or 30 June 2015. carries no right to fixed income.
Each share carries the right to one The Directors propose to renew these authorities at the 2015 Annual voteat general meetings of Hikma.
General Meeting for a further year.
In the year ahead, other than in respect of Hikmas obligations to satisfy rights granted to employees under its various share-based incentive arrangements, the Directors have no present intention of issuing any share capital of Hikma.
Details of the employee share schemes are set out in Note36 to the financial statements.
Shares are also held by the HikmaPharmaceuticals Employee Benefit Trust EBT and are detailed inNote 33 to the financial statements.
The EBT has waived its right tovote on the shares it holds and also to its entitlement to adividend.
No other shareholder has waived the right to a dividend.
112 Corporate governance Annual General Meeting review and up to the date of this report, and so far as the Company is aware, the independence provisions included in the relationship The Annual General Meeting of Hikma will be held at The Westbury, Bond Street, Mayfair, London W1S 2YF on Thursday, 14 May 2015, agreement with the Companys controlling shareholder have also been complied with during the period under review by the starting at 11.00 a. m. The Notice convening the meeting is given in a separate document accompanying this document, and includes controlling shareholder.
Additionally, the Independent Directors will be subject to approval at the 2015 Annual General Meeting by both a commentary on the business of the AGM, and notes to help shareholders exercise their rights at the meeting.
the shareholders of the Company as a whole and by a majority of the independent shareholders.
The powers of the Directors are determined by the Articles, theCode and other relevant UK legislation.
The Articles give the Pre-emptive issue of shares Directors the power to appoint and remove Directors.
The power During the year under review, and in the period since the date of toissue and allot shares contained in the Articles is subject to Hikmas Initial Public Offering on 1 November 2005, Hikma did shareholder approval at each Annual General Meeting.
The Articles, not issue any ordinary shares pursuant to an authority given by which are available on the website, may only be amended by special shareholders at an AnnualGeneral Meeting to issue ordinary shares resolution ofthe shareholders.
for cash on a non pre-emptive basis, other than in respect of the Directors interests placing undertaken on17 January 2008.
Details of Directors share-based incentives and interests in the Takeover panel Rule 9 ordinary shares of Hikma are provided in the Directors remuneration LTIP granted MIP granted report on pages 105 and 107.
16 May 2014 11 June 2014 Said Darwazah 97,000 Substantial shareholdings Mazen Darwazah 65,000 As at the date of this document, Hikma had been notified pursuant May Darwazah 444 to sections 89A to 89L of the Financial Services and Markets Act Hana Ramadan 4,773 2000 and Rule 5 of the Disclosure and Transparency Rules of the Tareq Darwazah 1,729 UKLA of the following interests in the voting rights attaching to the Zeena Murad 1,290 share capital of Hikma: Name of shareholder Number of shares Percentage held At the Annual General Meeting held on 15 May 2014, a vote Darhold Limited 57,183,028 28.79% of the independent shareholders of Hikma approved the award Capita Group International 17,558,981 8.84% of up to an aggregate of 150,600 ordinary shares pursuant to Fidelity International 9,873,932 4.97% Hikmas 2005 Long Term Incentive Plan to Said Darwazah, Mazen Darwazah and Hana Ramadan the LTIP Holders and 15,000 Messrs Said Darwazah, Mazen Darwazah and Ali Al-Husry, each being a Director and shareholder of Hikma, are shareholders and non-executive Directors of Darhold Limited.
ordinary shares pursuant to the Management Incentive Plan to May See page107 for details of their holdings in Darhold Limited Darwazah, Zeena Murad, Tareq Darwazah and Walid Darwazah the MIP Holders.
Because of the relationship of the LTIP Holders Controlling shareholder and the MIP Holders with Darhold Limited, who at the time of the During 2014, the Listing Rules were amended to introduce additional Annual General Meeting held 57,183,028 ordinary shares at 8 April requirements for companies with controlling shareholders.
2014 representing 28.76% of the issued share capital of Hikma, Darhold Limited and the Concert Party as detailed in the Notice andas at 10 March 2015 being the latest practicable date prior ofAnnual General Meeting, which accompanies this document are to thepublication of this document, holding 57,183,028 ordinary a controlling shareholder in Hikma.
Accordingly, in advance of the shares, representing 28.76% of the issued share capital of Hikma, provisions coming into force, the Company put in place a relationship each of the LTIP Holders and the MIP Holders together with certain agreement with them which complies with the required provisions, other identified individuals at that date was treated as acting in including the necessary independent undertakings.
This includes concert with Darhold Limited for the purposes of the Takeover Code transactions and arrangements with the controlling shareholder will the Concert Party.
As at 8 April2014, the Concert Party held, be conducted at arms length and on normal commercial terms: inaggregate, interests in 62,743,049 ordinary shares in the capital neither the controlling shareholder nor any of its associates will take of Hikma then representing 31.66% of the then issued share capital any action that would have the effect of preventing the Company of Hikma.
As at 10 March 2015 being the latest practicable date from complying with its obligations under the Listing Rules: and prior to the publication of this document, the Concert Party held, neither the controlling shareholder nor any of its associates will in aggregate, interests in 62,743,049 ordinary shares in the capital propose or procure the proposal of a shareholder resolution which of Hikma representing 31.66% of the then issued share capital is intended or appears to be intended to circumvent the proper of Hikma.
application of the Listing Rules.
The terms of the relationship agreement have been complied with throughout the year under 113 Hikma Pharmaceuticals PLC Annual Report 2014 DIRECTORS REPORT continued Holding if all existing SOP, Holding if maximum award Holding, 8 April 2014 Holding, 10 March 2015 MIP, LTIP are exercised granted in 2014 exercised No.
of Percentage of ordinary issued share ordinary issued share ordinary issued share ordinary issued share shares capital shares capital shares capital shares capital Darhold Limited 57,183,028 57,183,028 28.76% 57,183,028 28.79% Concert Party 62,743,049 62,743,049 31.66% 62,075,779 31.25% 62,554,931 31.49% 62,672,931 On full exercise of the options under the Hikma Pharmaceuticals The Directors are responsible for keeping adequate accounting 2004 Stock Option Plan the 2004 Plan and full vesting of the LTIPs records that are sufficient to show and explain the Companys and the MIPs, the Concert Party would potentially have, in aggregate, transactions and disclose with reasonable accuracy at any time the interests in 62,075,779 shares in the capital of Hikma representing financial position of the Company and enable them to ensure that 31.25% of the enlarged issued share capital of Hikma, on the basis the financial statements comply with the Companies Act 2006. that no ordinary shares were issued other than pursuant to the They are also responsible for protecting shareholder investments exercise of such options or vesting of LTIPs MIPs.
and safeguarding the assets of the Company and hence for taking During the period from the Annual General Meeting in 2014 to reasonable steps for the prevention and detection of fraud and 10 March 2015, the LTIP MIP Holders together with other members other irregularities.
of the Concert Party who hold options over ordinary shares pursuant The Directors are responsible for the maintenance and to Hikmas 2005 Long Term Incentive Plan and 2009 Management integrity of the corporate and financial information included on the Incentive Plan each an Option Holder exercised, in aggregate, Companys website.
Legislation in the United Kingdom governing options over 133,095 ordinary shares in the capital of Hikma.
the preparation and dissemination of financial statements may differ from legislation inother jurisdictions.
Directors Responsibility Statement We confirm to the best of our knowledge: Directors are responsible for preparing the Annual Report and the Financial Statements in accordance with applicable law and f The financial statements, prepared in accordance with International regulations.
Company law requires the Directors to prepare financial Financial Reporting Standards, give a true and fair view of the assets, statements for each financial year.
Under that law the Directors are liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole required to prepare the Group financial statements in accordance with International Financial Reporting Standards IFRSs as adopted f The Strategic report includes a fair review of the development and by the European Union and Article 4 of the IAS Regulation and have performance of the business and the position of the Company and the also chosen to prepare the Parent Company financial statements undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face under IFRSs as adopted by the EU.
Under company law the Directors must not approve the accounts unless they are satisfied that they give f The Annual Report and Financial Statements, taken as a whole, are fair, a true and fair view of the state of affairs of the Company and ofthe balanced and understandable and provide the information necessary forshareholders to assess the Companys performance, business model profit or loss of the Company for that period.
In preparing these and strategy financial statements, International Accounting Standard 1 requires that Directors: f Properly select and apply accounting policies By order of the Board f Present information, including accounting policies, in a manner that Said Darwazah, Chief Executive Officer provides relevant, reliable, comparable and understandable information 11 March 2015 f Provide additional disclosures when compliance with the specific requirements in IFRSs are insufficient to enable users to understand Mazen Darwazah, Executive Vice Chairman theimpact of particular transactions, other events and conditions 11 March 2015 ontheentitys financial position and financial performance f Make an assessment of the Companys ability to continue asagoingconcern 114
